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Introduction: New generations of parenteral lipid emulsions combine Long Chain Triglycerides (LCTs)
with Medium Chain Triglycerides (MCTs) either by physically mixing MCT- and LCT-containing oils or by
using synthetically structured triglycerides (STGs). In order to clarify some open issues relating to their
comparative effect, in particular in terms of clinical outcomes, pertinent evidence was systematically
identiﬁed, reviewed and meta-analyzed.
Methods: PubMed, Scopus, Wanfang Data, China Hospital Knowledge Database and Google Scholar were
searched for published clinical trials comparing STGs vs. MCTs/LCTs PN regimens administered over 5e7
days in surgical and/or critically ill patients. Two independent investigators performed screening and
data extraction using a predeﬁned list of parameters. Data were pooled using RevMan® 5.2. Quality of
evidence was assessed according to Cochrane's risk of bias tool. Pre-speciﬁed high quality (HQ), incre-
mental analyses and a post hoc subgroup analysis were performed.
Results: 21 studies were included. The meta-analysis revealed a signiﬁcantly better cumulative nitrogen
balance (Std. mean difference [95% CI]) (1.34 [0.98e1.7], p < 0.00001), as well as higher values for pre-
albumin (24.99 mg/L [6.71e43.27], p < 0.000001), and albumin (1.22 g/L [0.66e1.77] p < 0.0001), while
plasma triglycerides were signiﬁcantly lower (0.28 mmol/L [0.41 to 0.15], p < 0.0001) in the STG vs.
MCT/LCT group. ALT, AST, and GGT were signiﬁcantly lower with STGs than with MCTs/LCTs, while for
total bilirubin and ALP only a trend was observed. STGs were also associated with a trend to a shorter
hospital length of stay (LOS) (1.74 days [3.49 to 0.01] p ¼ 0.05). Quality of evidence was affected by an
unclear risk of selection bias, mostly due to the lack of detailed reporting (random sequence generation,
allocation concealment). For the other domains, most of the weighted information was judged at low risk
of bias. HQ estimated effects, incremental and subgroup analyses were consistent with the main analysis.
Conclusions: In postsurgical and/or critically ill patients, the administration of STGs vs. MCT/LCTs was
signiﬁcantly associated with improved protein economy, better liver tolerance and a more efﬁcient tri-
glyceride elimination. With regard to clinical outcomes a strong trend towards reduced LOS was
observed for STG patients.
© 2016 The Authors. Published by Elsevier Ltd and European Society for Clinical Nutrition and
Metabolism. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Parenteral nutrition (PN) is indicated in critically ill patients
who are malnourished or at risk of malnutrition and have ai).
Ltd and European Society for Clini
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ll adult patients: Systematic rdysfunctional gastrointestinal (GI)-tract not suitable for adequate
enteral feeding [1]. Lipids are an essential component of PN, not
only as an energy-dense source of calories within PN formulations
but also due to their importantmetabolic and functional properties,
e.g. as building blocks for membrane phospholipids, carriers for fat-
soluble vitamins, providers of essential fatty acids, and precursors
for important bioactive lipid mediators with the ability to inﬂuence
inﬂammation and immunity [2e4].cal Nutrition and Metabolism. This is an open access article under the CC BY-NC-ND
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G.H. Wu et al. / Clinical Nutrition xxx (2016) 1e122Triacylglycerols (TGs) consisting of three fatty acids (FA)
attached to a glycerol backbone are the primary components of
parenteral lipid emulsions. FA and their corresponding TGs may
be classiﬁed according to their chain length, number, and position
of double-bonds. For use in PN, both medium chain triglycerides
(MCTs, 6e12 carbons), or long chain triglycerides (LCTs; >14
carbons) based lipid emulsions represent possible alternatives
[4,2]. First generation lipid emulsions were mainly based on LCTs
from soybean oil. Nowadays this approach is not considered
optimal since soybean-based lipid emulsions are known to be
associated with a number of adverse immunological and pro-
oxidative effects due to the excessive supply of the u-6 FA lino-
leic acid [5]. As a possible alternative, in several second- and
third-generation parenteral lipid emulsions LCTs have been
partially replaced by MCTs. MCTs provide rapidly available en-
ergy; they do not accumulate in the liver, and are not susceptible
to lipid peroxidation. They are, however, not suitable as a sole
lipid source since they are composed of saturated FA only and
therefore lack essential fatty acids and their metabolism gives rise
to ketone bodies [6,7].
Two approaches are feasible to enable the combined adminis-
tration of LCTs and MCTs within a parenteral lipid emulsion: (1)
physical mixtures of MCTs derived from coconut or palm kernel oil
and LCT-containing oils (soybean, olive and/or ﬁsh oil) or (2) syn-
thetically structured triglycerides (STGs). The latter are obtained by
mixing MCTs (derived from coconut oil or palm kernel oil) and LCTs
from soybean oil and subsequent hydrolysis to liberate free FA and
glycerol. These compounds are then re-esteriﬁed at random,
resulting in the formation of mixed triglyceride molecules with
both medium-chain and long-chain fatty acids bound to the same
glycerol backbone [6,8]. In experimental settings, it has been
repeatedly demonstrated that PNwith STG-based lipid emulsions is
apparently more advantageous in terms of weight gain, nitrogen
(N) balance, and serum albumin concentration than either MCTs,
LCTs, or a physical mixture of both [9,10]. However, ﬁndings from
studies in surgical [11e13] and ICU-patients [14] have yielded
inconsistent outcomes. In 2006, Chambrier et al. [8] reviewed the
available literature on the use of STG-based lipid emulsions in the
clinical setting. Even though the authors were able to identify some
clear advantages of STG-emulsion compared to LCTs or physical
mixtures, e.g. with regard to parameters of liver function, at that
time their overall conclusion was that the results from human
clinical studies were less promising than the animal studies.
Moreover, they were unable to identify any studies evaluating
clinically relevant endpoints such as infectious complications,
morbidity, length of stay and/or mortality [8].
Zhou et al. conducted a systematic search and meta-analysis of
randomized controlled trials (RCT) on the use of STGs in PN pub-
lished before March, 2005 and ﬁnally included ten RCTs involving
236 patients. In 8 studies, a conventional soybean-based LCT
emulsion was used for comparison while only two of the studies
identiﬁed compared STGs to physical MCT/LCT mixtures which
were ﬁnally not included in the meta-analysis [15]. Authors
concluded that STG-based lipid emulsions were generally safe and
well tolerated. STGs had signiﬁcant effects on resting energy
expenditure, plasma glycerol, free FA (FFA), and b-hydroxybutyric
acid. Presumably due to the small sample size and the heteroge-
neity of patients, no differences in nitrogen balance could be
revealed by the meta-analysis of Zhou et al. Seven years later,
another group of investigators [16] conducted a similar research
identifying 21 studies, published in English or Chinese, with 833
participants (patients & volunteers). Thereof, 8 studies compared
STGs to pure LCTemulsionwhile 13 studies compared STGs toMCT/
LCT mixtures, all studies were combined for the purpose of the
meta-analysis. This time, the meta-analysis revealed signiﬁcantPlease cite this article in press as: Wu GH, et al., Structured triglycerides v
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balance. The authors thus concluded that STGs may represent a
promising alternative to other types of lipid emulsions for critically
ill patients, in particular for those with liver dysfunction and
hypertriglyceridemia [16].
There are, however, still open questions, especially on the dif-
ferences between the most comparable lipid emulsions MCT/LCT
and STGs. The present meta-analysis is based only on clinical
studies, excluding those in animals or volunteers and does not mix
MCT/LCT with LCT studies. Consequently, we systematically iden-
tiﬁed, reviewed and analyzed the relevant evidence comparing
STG-based lipid emulsions with physical MCT/LCT mixtures in PN
and conducted a meta-analysis to identify potential differences in
nutritionally and clinically relevant endpoints in surgical and/or
critically ill patients.
2. Methods
2.1. Research question and eligibility criteria
Eligible studies were intervention studies in surgical and criti-
cally ill adult patients receiving parenteral nutrition (PN) for
approximately 5e7 days, comparing STGs (Structolipid®) vs. MCT/
LCT (Lipofundin® MCT, Lipovenoes® MCT) as lipid source within a
isocaloric and isonitrogenous PN regimen, including as well glucose
and amino acids. Criteria for inclusion were: 1) clinical trial,
including observational ones, 2) at least one arm assigned to STGs
administered as PN and 3) investigating at least one of the
parameter as speciﬁed in a predeﬁned list of laboratory and clinical
outcomes (Tables 1 and 2). Minimum treatment duration of ﬁve
days was considered appropriate to capture effects of the lipid
regimen on the endpoint(s) of interest. In case relevant parameters
were not assessed on day 5, any available time point beyond day 5
was considered for the meta-analysis. Trials were excluded if they
1) involved children, 2) were unsuitable to investigate the pre-
deﬁned outcomes 3) weren't available as full articles, 4) were
considered to contain unreliable data (e.g. retracted papers).
2.2. Search strategy
The following databases were searched on October 10th, 2013:
PubMed, Scopus (subject area: medicine and nursing), Wanfang
Data, China Hospital Knowledge Database and Google Scholar. For
PubMed and Scopus, the search string was: “(structured triglyc-
eride OR structural lipid OR structured lipid) AND parenteral”
with limits imposed to publication type (Clinical Trial OR
Comparative Study OR Randomized Controlled Trial OR Clinical
Trial, Phase III OR Clinical Trial, Phase IV OR Controlled Clinical
Trial) AND Languages (English OR Chinese OR Italian OR French
OR German OR Spanish). For Chinese databases, the search was
restricted to humans and clinical trials. Studies found in more
than one database were identiﬁed though manual check and then
excluded from one of the lists to avoid duplicates. Chinese papers
were translated by biomedical professional translators. Two in-
dependent investigators performed the screening and selection
of studies, ﬁrstly, based on title and, secondly, on full text. At the
end of each step of the selection the investigators compared their
results and, in case of disagreement, consensus was sought.
Manual review of the references list of the selected articles was
performed.
2.3. Data collection
A data collection sheet was set up to assign data to four cate-
gories (descriptive, lab, clinical and comment). In case data on aersus physical mixtures of medium- and long-chain triglycerides for
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Table 1
List of collected laboratory outcomes.
Parameter Observation time Unit Conversion factor Outcome type
Nitrogen balance (cumulative) f g or mg/kg C
Pre-albumin b, f mg/L C
Albumin b, f g/L C
Respiratory quotient b, f Adimensional C
Resting energy expenditure b, f KJ/d C
Triglycerides b, f mmol/L mg/dl  0.0113 C
Cholesterol b, f mmol/L mg/dl  0.0259 C
High density lipoprotein cholesterol b, f mmol/L mg/dl  0.0259 C
Low density lipoprotein cholesterol b, f mmol/L mg/dl  0.0259 C
Plasma glycerol b, f mcmol/L C
Free fatty acids b, f mmol/L mg/dl  0.035 C
Malondialdehyde b, f mmol/mL C
Glutathione peroxidase b, f Unit of activity C
Aspartate aminotransferase b, f IU/L mcKat/l  58.82 C
Alanine transaminase b, f IU/L mcKat/l  58.82 C
Alkaline phosphatase b, f IU/L mcKat/l  58.82 C
Gamma-glutamyl transferase b, f IU/L mcKat/l  58.82 C
Total bilirubin b, f mg/dl mcmol/l  0.0585 C
Glucose b, f mmol/L mg/dl  0.0555 C
Serum creatinine b, f mcmol/L mg/dl  88.4 C
C-reactive-protein b, f mg/L C
b: basal, f: ﬁnal, C: continuous.
Table 2
List of collected clinical outcomes.
Outcome Unit Note Outcome
type
Hospital-length
of stay (mean, SD)
Days C
ICU-length of stay
(mean, SD)
Days Pooled in the event
of lack of data
C
Apache II (mean, SD) Score e C
Mortality rate N pts e D
Infection rate N pts or
N events
e D/Co
Adverse events
(open ﬁeld)
N pts or
N events
e D/Co
SD: standard deviation, C: continuous outcome, D: dichotomous, Co: counts (mul-
tiple events/patient).
G.H. Wu et al. / Clinical Nutrition xxx (2016) 1e12 3considered outcome were only displayed in a graphical way, the
software Engauge® was used to digitalize the curves and extrapo-
late numerical values. Data entry, both for the laboratory and the
clinical sections, was carried out by two independent investigators
and then compared for completeness and accuracy.
2.4. Assessment of risk of bias in individual studies
For assessment of the risk of bias in individual studies, the
Cochrane Collaboration's recommended tool was used. This tool
comprises six domains of bias: sequence generation and allocation
concealment (selection bias), blinding of participants and
personnel (performance bias), blinding of outcome assessors
(detection bias), attrition bias, reporting bias, and other bias [17],
thus enabling the most reliable assessment of the internal validity
of a study [18]. Critical assessment and judgment (low, high, and
unclear risk) for each of the domains were performed separately,
both at study and at outcome level.
2.5. Data synthesis
For continuous outcome parameters, mean difference was used
as effect measure; and standardized mean difference was used in
case of inconsistency of measurements, e.g. use of different scales
or units. Relative risk was used as effect measure for dichotomous
outcome parameters. For outcome parameters referring to an event
a patient may experience more than once, the number of eventsPlease cite this article in press as: Wu GH, et al., Structured triglycerides v
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person-years) and used as effect measure. Data from included
studies were statistically combined through meta-analysis utilizing
RevMan® 5.2. A ﬁxed-effect method was adopted to carry on the
meta-analysis; when a substantial heterogeneity (i2 > 50%) was
detected, a random effect model was adopted. For continuous data
the inverse variance method was adopted to weigh the studies.
When dichotomous outcomes were analyzed, the weighing of the
studies was performed by adopting the Mantel-Haenszel method,
which is preferable for small studies. The approach for the random-
effects meta-analysis was the DerSimonian and Laird method,
based on the inverse-variance approach, adjusting for the study
weights according to the extent of variation, or heterogeneity,
among the varying intervention effects. Inter-study variation was
estimated by comparing each study's result with a Mantel-
Haenszel or an inverse-variance ﬁxed-effect meta-analysis result,
according to the methods chosen for the ﬁxed effect.2.6. Risk of bias across studies
For outcome data characterized by at least 6 values, a funnel plot
of the intervention effect estimates for the individual studies against
measures of study size or precision was constructed in order to
investigate the possibility that nature and direction of the results
could have inﬂuenced their publication (publication bias) [19]. In
case an asymmetrical appearance of the funnel plot suggested the
presence of bias and at least 10 studies had contributed to the
outcome, a formal symmetry test was performed. The statistical
approach used for continuous outcomes was linear regression of the
effect estimates on their standard errors, weighed by the inverse of
the variance of the effect estimate. For risk ratios measured on
dichotomousoutcomes andcounts of events, no guidance is available
at the moment; thus no formal test was performed in those cases.2.7. Additional analysis
Beside the main analysis (all studies), a high quality (HQ) anal-
ysis on main outcomes was performed including only studies with
a low risk of bias according to the Cochrane tool (no key domain
receiving the judgment of high risk and not more than one key
domain receiving the judgment of unclear risk).ersus physical mixtures of medium- and long-chain triglycerides for
eview and meta-analysis, Clinical Nutrition (2016), http://dx.doi.org/
G.H. Wu et al. / Clinical Nutrition xxx (2016) 1e124Under the hypothesis that the ﬁnal outcome is correlated to the
value recorded at baseline (usually before the ﬁrst infusion), an
incremental analysis (difference between ﬁnal and basal value for
STGs vs. same difference for competitors) was conducted to better
capture the real effect of the different treatments. For the main
outcomes, we performed a linear regression analysis of the ﬁnal
values versus the correspondent basal values. In case a statistically
signiﬁcant correlation was detected, we proceeded to incremental
analysis, using the coefﬁcient of determination to adjust SD of the
difference between ﬁnal and basal values.2.8. Post-hoc subgroup analysis
A-posteriori, two main patient subgroups were identiﬁed: sur-
gical and non-surgical ICU subjects. Surgical populations include
patients receiving elective abdominal surgery, comprising colo-
rectal surgery, hepatobiliary surgery, prosthesis for abdominal
aortic aneurysm/atherosclerotic obstruction, surgery for gastroin-
testinal or liver neoplasm, and other middle-sized operations. Non-
surgical ICU patients were affected by COPD, serious heart failure,
severe sepsis/septic shock, trauma, severe infection, middle/severe
drug poisoning, or colon cancer. Due to the scarcity of studies
involving medical patients, non-surgical ICU subgroup analysesFig. 1. PRISMA ﬂow diagram of t
Please cite this article in press as: Wu GH, et al., Structured triglycerides v
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outcomes were liver function parameters; consequently, cirrhotic
patients were excluded from both patient groups deﬁned by this
classiﬁcation.3. Results
3.1. Study selection
A ﬂow chart showing the stages of study selection with reasons
for exclusion is shown in Fig.1. In the end, 21 studies were included,
characteristics of which are reported in Table 3, including the
amount of lipid emulsion [12,13,20e38].3.2. Outcome parameters of interest
Cumulative nitrogen balance was reported in eight studies.
Cumulative values (over a period of 5/6 PN days, according to each
study) were used. In most studies nitrogen-balance was expressed
as grams of nitrogen for the respective days, except for Mao et al.
[29] and Wu et al. [36] expressing nitrogen-balance as mg/kg body
weight. The meta-analysis shows a signiﬁcantly better nitrogenhe stages of study selection.
ersus physical mixtures of medium- and long-chain triglycerides for
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Table 3
Characteristics of included studies. Bold characters for the outcomes considered in the meta-analysis.
First author,
year (reference)
Country Population Age, mean
(SD)
Design Lipid regimen ITT Observation
index
Considered outcomes
Bi, 2013 [20] China Patients with gastrointestinal
tumor
Post-operative PN
61.5 (N/A) Randomized,
controlled
1.0 g/kgBW/day
for at least 5
days
64 POD 1e6 N balance, REE, CRP, GSH,
MDA
Chambrier,
1999 [13]
France Patients with elective
abdominal surgery
Post-operative PN
64 (11) Randomized,
double-blind,
controlled
0.85 g/kgBW/
day for at least
5 days
40 POD 1e6 N balance, PA, Alb, AEs
Chen, 2013 [21] China Critically ill ICU patientsa 68 (6.8) Randomized,
controlled
250 mL of 20%
emulsion daily
for 10 days
80 Day 0e5 AST, ALT, ALP, T Bil, TG, C,
HDL-C, LDL-C, AEs
Chen, 2013 [22] China ICU patients with severe sepsisa 71 (7.4) Randomized,
controlled
1.0 g/kgBW/day
for one week
64 Day 1e7 AST, ALT, TG, PA, Alb, C, G,
LOS ICU, Apache II,
Mortality rate.
Jing, 2010 [23] China Patients undergoing
hepatectomy
Post-operative PN
49.9 (8.6) Randomized,
double-blind,
controlled
500 mL of 20%
emulsion daily
for 5 days
125 POD 1e3/5 AST, ALT, T Bil, Alb, C, Serum
Cre, LOS H
Kang, 2011 [24] China Surgical patients with
hyperbilirubinemia
Post-operative PN
55.2 (10.7) Retrospective,
controlled,
matched
1.0 g/kgBW/day
for at least 5
days
50 POD 1e5 AST, ALT, ALP, GGT, T Bil, TG
Kruimel, 2001
[12]
The
Netherlands
Aortic prosthesis placement
patients
Post-operative PN
67 (6) Randomized,
double-blind,
controlled
Lipids to cover
26% of ER for 5
days
25 POD 1e5 N balance, TG, FFA
Li, 2011 [25] China Critical ill ICU patientsa 38e68 Randomized,
controlled
42 kJ/kgBW/
day for 6 days
40 Day 0e6 AST, ALT, GGT, TG, PA, C,
Serum Cre
Lu, 2012 [27] China ICU patients in need for PNa 55.1 (7.9) Randomized,
controlled
1.0 g/kgBW/day
for at least 5
days
61 Day 0e5 TG, PA, Alb, C, G, AEs
Lu, 2012 [26] China Patients with gastrointestinal
tumor
Post-operative PN
49.3 (8.5) Randomized,
double-Blind,
controlled
1.0 g/kgBW/day
for at least 6
days
80 POD 1e7 LOS H, Inf, AEs
Luo, 2011 [28] China Patient with major abdominal
surgery
Post-operative PN
60(16) Randomized,
controlled
~410 mL of 20%
emulsion daily
for 5 days
40 Daya,b 0e5 TG, Inf, AEs
Mao, 2010 [29] China Patients with gastrointestinal
tumor
Post-operative PN
49.3 (8.5) Randomized,
double-Blind,
controlled
1.0 g/kgBW/day
for at least 6
days
80 POD 1e7 N balance, PA, Alb, Inf, AEs
Puiggros, 2009
[30]
Spain Patient with major
gastrointestinal surgery
Post-operative PN
62.4 (13.2) Randomized,
double-blind,
controlled
1.1e1.2 g/
kgBW/day for 5
days
14 POD 1/2e5 AST, ALT, ALP, GGT, T Bil,
TG, C, HDL, LDL
Shi, 2006 [31] China Patients with gastrointestinal
surgery
Post-operative PN
55.9 (9.2) Randomized,
blind,
controlled
1.0 g/kgBW/day
for 5 days
60 POD 1e6 TG, PA, C
Su, 2012 [32] China Patients with blood
loss > 3000 mL before or during
surgery
Post-operative PN
54.5 (9.1) Randomized,
controlled
1.0 g/kgBW/day
for 5 days
20 POD 2e5/7 ALT, T Bil, TG, PA
Wang, 2005
[34]
China Patients with abdominal
surgery
Post-operative PN
44 (17) Randomized,
double-blind,
controlled
1.0 g/kgBW/day
for 5 days
24 POD 1e6 N balance, PA, LOS H
Wang, 2006
[35]
China Patients with abdominal
surgery
Post-operative PN
48 (15) Randomized,
blind,
controlled
1.0 g/kgBW/day
for 5 days
40 Before and after
injection at 2 nd
PN day
TG, C
Wu, 2013 [36] China Surgical patients with liver
cancer
Post-operative PN
49.1 (1.8) Randomized,
controlled
1.0 g/kgBW/day
for 6 days
66 POD 0e7 N balance, AST, ALT, T Bil,
PA, Alb, AEs
Yu, 2008 [37] China Patients with abdominal
surgery
Post-operative PN
(N/A) Randomized,
controlled
500 mL of 20%
emulsion daily
for 5 days
50 POD 5 AST, ALT, AEs
Yuan, 2012 [33] China Cirrhotic patientsa
Inpatient PN
59.3 (14.2) Controlled 1.0 g/kgBW/day
for 7 days
26 Day 1e6 N balance AST, ALT, T Bil,
PA, Alb, AEs
Zhuo, 2010 [38] China Hepatic surgery patients
Post-operative PN
50 (14) Randomized,
double-blind,
controlled
1.0 g/kgBW/day
for 6 days
86 POD 1e7
(6 for N balance)
N balance, T Bil, PA, Alb
a Studies in non-surgical patients.
b Authors didn't report the exact day after surgery in which they started PN; POD: post-operative day, BW: body weight, ER: energy requirement, N: Nitrogen, TG: tri-
glycerides, LOS: length of stay, REE: Rest Energy Expenditure, CRP: c-reactive-protein, GSH-px: glutathione peroxidase, MDA: malondialdehyde, PA: pre-albumin, Alb: al-
bumin, AST: aspartate aminotransferase, ALT: Alanine transaminase, ALP: alkaline phosphatase, T Bil: total bilirubin, C: cholesterol, HDL-C: high density lipoprotein
cholesterol, LDL-C: low density lipoprotein cholesterol, AEs: adverse events, G: glucose, Cre: creatinine, GGT: Gamma-glutamyltransferase, FFA: fatty free acids, RQ: respi-
ratory quotient, Inf: infections, LT: long term.
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(Fig. 2A).
Prealbumin (PA) and serum albumin (Alb) measured after 5e7
days of PN were reported in eleven and eight studies respectively.Please cite this article in press as: Wu GH, et al., Structured triglycerides v
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for STGs emulsion compared to the physical mixture (Fig. 2B and C).
Meta-analysis could not be performed for the other nutritionalersus physical mixtures of medium- and long-chain triglycerides for
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Fig. 2. Forest plots of the meta-analysis for the effect of STGs vs. MCT/LCT on laboratory parameters.
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Table 4
Effect estimated by main, high quality (HQ), incremental and subgroup analyses.
Outcome Analysis Studies Participants Effect estimate [95% CI]
N balance (Commulative-g, Std. Mean Difference, ﬁxed) Main analysis 8 390 1.35 [1.12, 1.57]
High quality analysis 2 146 1.10 (0.75,1.44)
Subgroup: surgical 7 367 1.34 [1.11, 1.57]
Albumine (g/L, Std. Mean Difference, ﬁxed) Main analysis 8 537 1.22 [0.66, 1.77]
High quality analysis 3 184 1.47 (0.43; 2.51)
Incremental analysis 8 540 1.21 [0.60, 1.81]
Subgroup: surgical 5 395 1.12 [0.41, 1.83]
Subgroup: non-surgical ICU 2 119 1.38 [0.48, 2.28]
Plasma TG (mmol/L, Mean difference, random) Main analysis 11 504 0.27 (0.32; 0.21)
High quality analysis 4 214 0.30 (0.48; 0.11)
Subgroup: surgical 7 265 0.27 [0.51; 0.04]
Subgroup: non-surgical ICU 4 239 0.30 [0.46; 0.14]
ALT (IU/L, Mean Difference, Random) Main analysis 10 526 4.39 (5.97; 2.82)
High quality analysis 4 210 3.95 [6.18, 1.73]
Incremental analysis 8 421 0.75 [3.82; 2.32]
Subgroup: surgical 6 325 12.63 [25.99, 0.73]
Subgroup: non-surgical ICU 3 178 4.81 [6.43, 3.20]
AST (IU/L, Mean difference, random) Main analysis 9 506 6.01 (6.15; 5.87)
High quality analysis 4 210 6.01 [6.15, 5.87]
Incremental analysis 7 401 3.02 [6.32, 0.27]
Subgroup: surgical 5 305 6.00 [6.14, 5.85]
Subgroup: non-surgical ICU 3 178 6.48 [7.39, 5.56]
ALP (IU/L, Mean Difference, Fixed) Main analysis 3 144 2.47 (6.46; 1.53)
High quality analysis 2 94 2.05 [6.08, 1.98]
Subgroup: surgical 2 64 28.99 [59.38, 1.41]
GGT (IU/L, Mean Difference, Fixed) Main analysis 3 104 2.00 (2.98; 1.03)
Subgroup: surgical 2 64 3.03 [19.59, 13.53]
Total bili (mg/d, Mean Difference, Random) Main analysis 8 464 0.09 (0.24; 0.06)
Incremental analysis 8 467a 0.05 [0.09, 0.19]
High quality analysis 5 304 0.15 [0.49, 0.19]
Subgroup: surgical 6 361 0.14 [0.33, 0.05]
Pre-Albumin (mg/L, Mean Difference, Random) Main analysis 11 575 24.99 (6.71; 43.27)
High quality analysis 4 264 23.55 (2.84; 49.94)
Incremental analysis 10 540 21.45 [1.06, 41.84]
Subgroup: surgical 7 393 31.00 [11.73, 50.26]
Subgroup: non-surgical ICU 3 159 32.00 [0.63, 64.63]
LOS (days, Mean Difference, Random) Main analysis 3 286 1.74 [3.49, 0.01]
Subgroup: surgical 3 228 1.45 [3.42, 0.53]
AE composite (Risk Ratio, Fixed) Main analysis 8 2839b 0.70 [0.50, 0.97]
Subgroup: surgical 6 1821b 0.68 [0.48, 0.97]
Subgroup: non-surgical ICU 2 1018b 0.86 [0.29, 2.57]
a Further three patients considered for the incremental analysis, compared to the main, since they have basal data.
b Patient-day.
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outcomes.
Eleven studies reported plasma TG values, measured after a 5e7
days of PN except for the study of Wang et al. [35], which assessed
TG values on the 2nd day after start of PN. With STGs, signiﬁcantly
lower plasma TG concentration after infusion could be shown
compared to physical mixtures of MCT/LCTs (Fig. 2D). For investi-
gation of other parameters of lipid metabolism or antioxidant sta-
tus, such as cholesterol, free fatty acids, plasma glycerol, MDA or
GSH-peroxidase, there was insufﬁcient data to perform a meta-
analysis.
Liver function parameters investigated were alanine trans-
aminase (ALT), aspartate aminotransferase (AST), alkaline phos-
phatase (ALP), gamma-glutamyl transferase (GGT), and total
bilirubin. Meta-analysis shows that administration of STGs is
associated with signiﬁcantly lower ALT, AST, and GGT values; for
total bilirubin and ALP the same trend is detected, but the differ-
ence doesn't reach statistical signiﬁcance (Fig. 2E, Table 4).Please cite this article in press as: Wu GH, et al., Structured triglycerides v
parenteral nutrition in surgical or critically ill adult patients: Systematic r
10.1016/j.clnu.2016.01.004Since only Chen et al. [22] reported data on length of stay (LOS)
in the intensive care unit (ICU), this outcome has been pooled with
hospital (H) LOS recorded by Jing et al. [23], Lu QQ et al. [26], and
Wang 2005 [34]. Our analysis revealed a strong trend towards
shorter LOS in patients receiving STGs (Fig. 3A). Regarding the
incidence of adverse events, the paucity of data for each single type
of event necessitated the generation of a composite outcome
comprising: infections, dorsalgia/back pain, nausea/vomiting,
headache, vertigo, fever/chills, allergic reaction, central nervous
system toxicities, rash/skin desquamation, abnormal blood pres-
sure, abnormal pulse rate, wound infection and any other type of
clinical adverse events. A statistically signiﬁcant lower risk to
experience an AE was associated with the administration of STGs
(Fig. 3B).
For other parameters, like total cholesterol, HDL, LDL, blood
glucose or serum creatinine, reported by only a few studies or for
which the relationship between different types of lipid intake and
inﬂuence on the effect is unclear, results of the meta-analysis are
detailed in Additional ﬁle 1.ersus physical mixtures of medium- and long-chain triglycerides for
eview and meta-analysis, Clinical Nutrition (2016), http://dx.doi.org/
Fig. 3. Forest plots of the meta-analysis for the effect of STGs vs. MCT/LCT on clinical outcomes.
G.H. Wu et al. / Clinical Nutrition xxx (2016) 1e128For all other laboratory and clinical outcomes, there was insuf-
ﬁcient data available to perform a meta-analysis.
3.3. Risk of bias in individual and across studies
Overall, regarding the methods adopted for random sequence
generation and allocation concealment, risk of selection bias was
rated “unclear” for 71% and 81%, “high” for 15 and 14%, and “low”
for 14% and 5%, respectively, of the studies. In the ﬁeld of attrition
biases, associated to the incompleteness of collected data about half
of the studies were rated to be at “low risk” of bias and 14% at “high
risk”. With regard to the selected outcomes for reporting, about half
of the studies were rated to be at high risk of bias, with lack of
clinical importance or of statistical signiﬁcance as usual reasons for
non-publication. The risk of blinding bias was dependent on the
subjectivity of the outcome (see Additional ﬁle 2).
The visual inspection of funnel plots related to the main out-
comes, together with formal test when it was necessary, doesn't
suggest evidence of signiﬁcant publication biases (more details in
Additional ﬁle 3).
3.4. Additional analyses
The effect estimated by HQ analyses (Table 4) is consistent with
that of the main analysis for nitrogen balance, Alb, TG, and liver
enzymes; merely the improved increment of PA associated to STGs
lost statistical signiﬁcance. Based on Cochrane Tool, only one study
was considered of high quality for H-LOS; furthermore both HQ-
trials contributing to AEs reported no event in the STGs group,
leading to a non-interpretable risk ratio estimate.
Outcomes for which quantity as well as the quality of data
permitted to detect a statistically signiﬁcant linear relationshipPlease cite this article in press as: Wu GH, et al., Structured triglycerides v
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0.61, p < 0.001), ALT (r2 0.72, p < 0.001), AST (r2 0.50, p < 0.005), and
total bilirubin (r2 0.81, p < 0.001); for these parameters we per-
formed an incremental analysis (Table 4). The meta-analysis of
ﬁnal-basal differences for nutritional markers (Alb, PA) indicates a
statistically signiﬁcant difference favoring STGs, consistently with
the corresponding estimate from the absolute value analysis. Yet,
AST and ALT result lost statistical signiﬁcance.
3.5. Post-hoc analysis: subgroup analysis
Results of the post-hoc subgroup analysis are given in Table 4.
Based on this post-hoc analysis, the administration of STGs pro-
vides a similar beneﬁt in both identiﬁed populations, except for ALT
and GGT values, in which the trend is maintained but the statistical
signiﬁcance is lost.
4. Discussion
4.1. Interpretation of main results
Innovative lipid emulsions, including STGs, have emerged as
promising alternatives to conventional soybean-based lipid
emulsions rich in u-6 fatty acids. STG-based lipid emulsions
combine the advantages of LCT- (provision of essential fatty acids)
and MCT-based emulsions (rapid clearance and oxidation). In the
present meta-analysis, we aimed to speciﬁcally elucidate potential
beneﬁts of STGs emulsions vs. MCT/LCT physical mixtures on
relevant metabolic parameters and clinical outcomes, including
length of hospital/ICU stay and complications, in surgical and
critically ill patients. Including 21 clinical trials in the ﬁnal quan-
titative analysis, we found the administration of STGs to beersus physical mixtures of medium- and long-chain triglycerides for
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plasma proteins, lower plasma TG, improved parameters of liver
tolerance, lower AE incidence and a trend towards a reduced
length of hospital stay.
Negative N-balance and/or subnormal levels of plasma proteins
are common markers of protein wasting and muscle protein
catabolism. These phenomena occur when exogenous energy
sources are unable tomeet the metabolic requirements of the body.
Critically ill and/or surgical patients included in the present anal-
ysis, usually experience substantial losses of body protein despite
nutritional support. Therefore one of the goals of the nutritional
support via EN or PN is to minimize the loss of lean body mass and
to protect muscle function. To measure cumulative nitrogen bal-
ance, like done in the studies included in thismeta-analysis, is more
useful than single measurements since it better reﬂects improve-
ment when the patient recovers from illness [39]. In surgical [11,12]
and in ICU-patients with sepsis or multiple injuries [14], a paren-
teral STG emulsion has been shown to improve nitrogen balance as
compared to an LCTemulsion or physical MCT/LCTmixtures. On the
other hand, in patients after major abdominal surgery, nitrogen
balance and urinary excretion of 3-methyl-histidine, a marker of
muscle protein hydrolysis, were not signiﬁcantly different between
the patients receiving STGs emulsion and those receiving physical
MCT/LCT mixture [13]. In the present meta-analysis pooling of data
on cumulative N-balance from 8 clinical trials showed a signiﬁcant
beneﬁcial effect with STGs emulsion compared toMCT/LCT physical
mixtures, with a standardized mean difference of 1.34 (95% CI:
0.98e1.7, p < 0.00001). These ﬁndings are in agreement with the
meta-analysis by Zhu 2013 [16] and indicate that that infusion of
STGs might induce a protein-saving effect in both surgical and ICU
patients. Moreover, in the present meta-analysis the plasma pro-
teins PA (mean difference: 24.99, 95% CI: 6.71e43.27, p < 0.000001)
and albumin (mean difference: 1.22, 95% CI: 0.66e1.77, p < 0.0001)
measured after 5e7 days of PN showed signiﬁcant positive effects
in favor of STGs compared to physical MCT/LCT mixtures. However,
while PA changes occur in the short term, albumin as a slow
reacting protein might be inadequate to reﬂect a 5e7 days protein
turnover (possibly not reported infusion of albumin as treatment
may also have confounded the values), therefore the effect on al-
buminwas only marginally considered. Our conclusions are mainly
based on improved nitrogen balance and increase in pre albumin
levels to support an improved protein economy and better nutri-
tional efﬁcacy.
These ﬁndings imply that STGs are more favorable than physical
MCT/LCT mixtures with regard to nutritional efﬁcacy in critically ill
and/or surgical patients. Considering that nutritional deﬁcits in
critical illness are prone to rapidly progress to malnutrition, even-
tually leading to increased complication rates and adverse out-
comes [40,2] this ﬁnding is of particular interest. The underlying
mechanisms for the improved protein economy with STG-based
emulsions have not yet been fully elucidated and have been
mainly explained by the differences between MCT and LCT. It has
been proposed that the effect is partly due to the more favorable
energy balance related to the higher cellular uptake and faster
oxidation rate of STGs compared to LCTs [8]. As revealed by kinetic
studies in rats, the metabolism of STGs is energetically more efﬁ-
cient than that of LCTs since it involves less energy-expending
cycling of FFA for the restoration of endogenous TG-stores [41].
Moreover, an increased production of ketone bodies, serving as an
alternative energy source for certain organs and inducing the
release of insulin, might contribute to the observed protein
anabolic effect [9]. The exact mechanism implied in the differences
on protein and energy economy between STGs and physical mix-
tures of MCT/LCT shown in this meta-analysis still remains an
interesting ﬁeld of investigation.Please cite this article in press as: Wu GH, et al., Structured triglycerides v
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tration of parenteral lipid emulsions is their effect on TG-levels.
Hypertriglyceridemia is one of the most frequent acute metabolic
complications of PN and has been reported to occur in 25e50% of all
treated patients [42]. As a general guideline, a serum TG level of
400 mg/dl should not be exceeded in order to avoid serious
metabolic derangements such as fat overload syndrome [43,44].
The impact of parenteral lipid infusion on plasma lipids is not only
related to the amount and rate of lipid administration [45] but also
to the type of lipid emulsion. In experimental setting, it has been
shown that both STGs emulsion and the physical mixture are
cleared more rapidly from plasma than LCT emulsion [46]. Also in
moderately catabolic patients, the STGs emulsion has been shown
to be eliminated faster from blood than a physical mixture of MCTs
and LCTs [12]. STGs emulsion also improved whole body lipid
oxidation compared with LCT emulsion in the postoperative state
[47]. Chambrier et al. [8], reviewing 7 human studies reporting on
TG plasma levels, reported conﬂicting results, with some studies
showing a faster clearance and higher oxidation of STGs compared
with other lipid emulsions while others showed no difference. In
the present review, the meta-analysis of 11 studies reporting on
this outcome revealed signiﬁcantly lower plasma TG values with
STGs vs. MCT/LCTemulsion, with amean difference of0.28mmol/
L (95% CI: 0.41 to 0.15, p < 0.0001), corresponding to 0.25 mg/
dl. The risk of developing hypertriglyceridaemia thus seems to be
reduced with a STG emulsion compared to the physical mixture of
MCT and LCT.
This ﬁnding is most likely related to the molecular structure of
the lipids. Two differences between the STG and MCT/LCT emul-
sions might explain the improvement in triglyceride elimination
and utilization.
Firstly, the identical weight contribution of MCT and LCT in the
physical mixture leads to a molecular overweight of the lighter
MCTs, the latter are distributed more closer to the surface of the
globule due to their hydrophilic property and are thus hydrolyzed
ﬁrst by the plasma lipoprotein lipase (LPL). This leads to a peak of
TG levels originating from MCT in the earlier phase with
a utilization of LCT at a later stage only. In contrast in STGs the
different types of triglycerides are evenly distributed in the lipid
globules and therefore do not lead to a separate hydrolysis of me-
dium chain fatty acids (MCFAs) and long chain fatty acids (LCFAs)
over time.
Secondly the random distribution of the equi-molar MCFAs and
LCFAs in STGs leads to 6 different molecular structures: MLM, LML,
LLM (¼MLL), MML (¼LMM), MMM and LLL Therefore in the STGs
mixture there are equal amounts of molecules of MCFAs and LCFAs
esteriﬁed to the positions 1 and 3. This leads to a balanced release of
MCFA together with LCFA, monoglycerides and glycerol. LCFAs,
which have a more lipophilic nature, are rapidly taken up and
metabolized by the cells while MCFAs are transported into the
mitochondria partly independent from carnitine where they are
efﬁciently oxidized. The uptake of both MCFAs and LCFAs in par-
allel, helps avoiding excess of LCFAs leading to a feedback inhibition
of lipolysis and enables to proﬁt from the advantage of each type of
FA. In summary, both elimination from the bloodstream and
cellular oxidation appear to be more effective for STGs, which could
at least partly explain the observed beneﬁcial effect on plasma TG
levels [46,9].
A gradual rise in serum levels of liver enzymes and bilirubin
within 1e2 weeks is a characteristic feature of PN and may ulti-
mately lead to severe hepatic complications in case of long term
administration [48,42]. The present meta-analysis revealed bene-
ﬁts of STG-based lipid emulsions over MCT/LCTmixtures on several
liver function parameters which were signiﬁcant for AST, ALT and
GGT and showed a positive trend for total bilirubin and ALP.ersus physical mixtures of medium- and long-chain triglycerides for
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GGT must be regarded with some caution due to the fact that over
95% of theweight was held by a single study (Yu and colleagues [37]
for AST, Chen and colleagues [21] for ALP, and Li and colleagues [25]
for GGT). For ALT this is not the case since 3 almost equally
weighted studies together with some smaller studies contribute to
the signiﬁcant outcome. Nevertheless, the ﬁnding that STGs
emulsions may beneﬁcially affect liver function tests underlines
their usefulness as a safe alternative lipid source in critically ill and
surgical patients, in particular those at risk for liver dysfunction.
With regard to their proven beneﬁcial effect on nutritional and
metabolic parameters, it could be expected that the use of STGs
would beneﬁcially inﬂuence clinical outcome. Based on the avail-
able study data, meta-analysis could merely be performed for the
clinical outcome parameters hospital/ICU LOS and risk of experi-
encing an AE.
We observed a strong trend towards a shorter length of stay in
patients receiving STGs; the meta-analysis of data from 4 studies
showing a mean difference of 1.74 days in favor of STGs (95% CI:
3.49 to 0.01) which reached borderline signiﬁcance (p ¼ 0.05).
The latter ﬁnding was somewhat unexpected since, in critically ill
and/or surgical patients, the length of hospital stay was expected to
be primarily related to the severity of the underlying condition or
the success of the surgical procedure. With regard to the other
clinical endpoints, disease severity (APACHE II), mortality and in-
fectious complications there were insufﬁcient data from the avail-
able studies to perform a meta-analysis.
In order to assess safety, adverse events were also investigated
wherever possible. Due to the paucity of information, low number
of events and the inconsistent criteria used for assessment in the
different trials, we decided to sum all kinds of AEs reported in all of
the studies, without considering their severity or relation to the
intervention. Even though it should thus be interpreted with some
caution, the result obtained from the meta-analysis of 9 studies
revealing a signiﬁcantly lower risk of experiencing an AE with STGs
compared to the physical mixtures (RR: 0.70, 95% CI: 0.50e0.97,
p ¼ 0.03), is deﬁnitely notable.
4.2. Comparison with previous evidence
To our knowledge this is the ﬁrst meta-analysis exclusively
including studies comparing STGs to physical mixtures of MCTs and
LCTs. Meta-analyses by two different groups of investigators
designed to evaluate the use of STG-based lipid emulsions
compared to either LCT or physical MCT/LCT mixtures, have been
published before [15,16]. However, only the more recent one [16]
included a sufﬁcient number of studies (n ¼ 13) using the phys-
ical mixture as a control to allow for a direct comparison with our
ﬁndings. Our results are in line with the overall conclusion by Zhu
et al. that STGs are rapidly metabolized without harming the liver
and beneﬁcially affecting N-balance. Of note, while in the previous
meta-analyses, reported outcomes were conﬁned to parameters of
safety and nutritional efﬁcacy, in the present evaluation, for the ﬁrst
time, clinically relevant endpoints have been considered.
With regard to statistical methods, there are some obvious dif-
ferences distinguishing the present evaluation from the previously
published meta-analyses. First of all, we used cumulative values
(over a period of 5/6 PN days) to account for the serial trend in N-
balance assessment. Furthermore, we decided to perform an
additional incremental analysis in case an obvious correlation be-
tween the ﬁnal and the basal value was detected as an approach to
optimally capture the real effect of a strategy. The results of the
incremental analysis were consistent with the primary analysis for
nutritional markers, while for AST and ALT statistical signiﬁcance
was lost (Table 4).Please cite this article in press as: Wu GH, et al., Structured triglycerides v
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Overall, the quality of the body of evidence available for the
evaluation of the main outcomes was rated as moderate on a 4-step
scale from very low to high. Five out of 21 studies included in the
present meta-analysis were rated as “small studies” with a sample
size of 40 or less. However, for the main outcome parameters only
about 15% of the estimated effect were derived from these small
studies.
A low percentage of studies judged at low risk of bias, in
particular with regard to selection bias, has been detected, repre-
senting a potential weakness of the present evaluation. It may be
partly explained by the predominance of studies with a lack of
detail in describing the adopted methodology, leading to the rating
“unclear risk of bias”. Likewise, also the risk of detection bias has
been judged high for most of the studies; however it's considered
relevant only for subjective parameters (only “composite AEs” in
the present analysis).
In order to take account of this problem, we conducted a pre-
deﬁned additional analysis on main outcomes based solely on
“high quality” evidence. Results were generally consistent with the
main analysis for N-balance, serum albumin, TG concentration and
liver enzymes, while the effect on pre-albumin failed to reach
statistical signiﬁcance. We suspected of two main sources of vari-
ability for the studies included: (1) the diagnosis/intervention
leading to hospital admission and (2) the time points when mea-
surements for laboratory outcomes were performed. A post-hoc
additional subgroup analysis was thus performed for the sub-
groups “surgical” and “non-surgical ICU patients”, without
revealing major differences from the main analysis (Table 4).
5. Conclusions
In the present meta-analysis including data from 21 clinical
trials in surgical and/or critically ill patients, the administration of
STGs was signiﬁcantly associated with improved protein economy
and nutritional efﬁcacy shown by a more positive cumulated ni-
trogen balance, as well as beneﬁcial effects on plasma TG elimi-
nation and lower liver enzyme levels indicating improved liver
tolerance. Moreover, for the ﬁrst time, it could be demonstrated
that patients receiving a STG-based lipid emulsion apparently
tended to a shorter overall length of hospital stay when comparing
to physical mixtures of MCTs and LCTs. Further well-designed and
adequately powered studies are necessary to determine the effects
of STGs administration on other meaningful outcome parameters
such as infectious complications, overall morbidity and mortality.
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